HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MoCRA Talc-Testing Rule Brings Clarity While Raising Target For Class Action Complaints

Executive Summary

The FDA’s proposed regulation for talc testing slated for release 29 December will eliminate uncertainty among scientific experts on what is the best method for identifying asbestos but will also give plaintiffs a stationary target for identifying when stakeholders are not in compliance.

You may also be interested in...

FDA Has Early Holiday Gift For Cosmetics Industry: More Time To Register Under MoCRA

The US Food and Drug Administration will delay enforcement of the first registration deadline for cosmetic facility manufacturers and cosmetic product listings under the Modernization of Cosmetics Regulation Act until 1 July, 2024.

‘Junk Litigation Opinions’: J&J’s Talc Liabilities Subsidiary Sues Plaintiff Experts For Disparaging Talcum Powders

What ails J&J in litigation concerning the alleged role of its Johnson’s Baby Powder and other talcum products in plaintiffs’ mesothelioma – ie, “tactics to pollute the scientific literature” – is a growing systemic problem, according to the firm’s wholly owned indirect subsidiary LTL Management.

J&J’s Talc Subsidiary Not ‘Financially Distressed’ Enough For Bankruptcy – Third Circuit

The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts